B. Riley Estimates Electromed's Q1 Earnings (NYSE:ELMD)

Key Points

• B. Riley raised its Q1 2026 earnings estimate for Electromed to $0.23 per share, up from a previous estimate of $0.20, maintaining a "Strong-Buy" rating for the stock.
• Roth Capital and Loop Capital updated their price targets for Electromed, with Roth increasing its target from $29.00 to $35.00, and Loop setting a target of $36.00.
• Electromed's stock recently opened at $24.77, with a market capitalization of $207.72 million and institutional investors owning approximately 40.82% of the shares.

Electromed, Inc. (NYSE:ELMD - Free Report) - Equities researchers at B. Riley raised their Q1 2026 earnings estimates for shares of Electromed in a research report issued on Wednesday, August 27th. B. Riley analyst A. Schock now expects that the company will post earnings per share of $0.23 for the quarter, up from their previous estimate of $0.20. B. Riley currently has a "Strong-Buy" rating on the stock. B. Riley also issued estimates for Electromed's Q2 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.29 EPS, FY2026 earnings at $1.04 EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.29 EPS, Q3 2027 earnings at $0.31 EPS, Q4 2027 earnings at $0.34 EPS and FY2027 earnings at $1.23 EPS.

Other equities analysts have also issued research reports about the company. Roth Capital lifted their price target on Electromed from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday. Loop Capital set a $36.00 price objective on shares of Electromed in a research note on Wednesday. Wall Street Zen downgraded shares of Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Lake Street Capital initiated coverage on shares of Electromed in a report on Wednesday. They set a "buy" rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $36.25.

Electromed Stock Performance

Shares of NYSE ELMD opened at $24.77 on Thursday. The company has a 50 day simple moving average of $19.73 and a two-hundred day simple moving average of $22.27. Electromed has a fifty-two week low of $13.74 and a fifty-two week high of $35.56. The company has a market capitalization of $207.72 million, a price-to-earnings ratio of 33.03 and a beta of 0.38.

Hedge Funds Weigh In On Electromed

Several hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC grew its holdings in shares of Electromed by 7.8% in the fourth quarter. Squarepoint Ops LLC now owns 11,366 shares of the company's stock worth $336,000 after acquiring an additional 823 shares during the period. American Century Companies Inc. boosted its position in Electromed by 3.1% in the second quarter. American Century Companies Inc. now owns 32,031 shares of the company's stock worth $704,000 after purchasing an additional 969 shares during the last quarter. Spire Wealth Management grew its stake in shares of Electromed by 22.7% during the 2nd quarter. Spire Wealth Management now owns 5,405 shares of the company's stock valued at $119,000 after purchasing an additional 1,000 shares during the period. Raymond James Financial Inc. increased its position in shares of Electromed by 1.8% during the 2nd quarter. Raymond James Financial Inc. now owns 58,331 shares of the company's stock valued at $1,283,000 after purchasing an additional 1,053 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Electromed during the 2nd quarter valued at about $32,000. 40.82% of the stock is owned by institutional investors.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.